Randomized phase II trial of zolbetuximab as second-line treatment in patients with claudin 18.2-positive advanced gastric/GEJ cancer with previous zolbetuximab exposure: ZELDA
C. Inagaki, E. Oki, K. Ando, H. Hirano, M. Furuta, Y. Narita, T. Esaki, K. Murotani, H. Kawakami, K. Muro · 2026
Read Randomized phase II trial of zolbetuximab as second-line treatment in patients with claudin 18.2-positive advanced gastric/GEJ cancer with previous zolbetuximab exposure: ZELDA by C. Inagaki, E. Oki, K. Ando, H. Hirano, M. Furuta, Y. Narita, T. Esaki, K. Murotani, H. Kawakami, K. Muro (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13583981.txt.
Description
Inagaki and co-authors set out a randomised trial asking whether a targeted antibody drug should continue after stomach cancer grows past it, in a 2026 paper. The drug, zolbetuximab, attacks a protein found on some stomach and junction cancers. Paired with chemotherapy, it is now standard first treatment for those patients. When the cancer later advances, patients usually switch drugs entirely. Whether keeping the antibody in the second round helps was unknown.
The trial, named ZELDA, enrolls patients whose tumours carry the target protein and who already received the drug in round one. They are assigned at random to standard second-line chemotherapy with or without the antibody again. The main question is whether the added drug lengthens survival. The rationale is that tumours keep the target protein after chemotherapy, and no clear escape route from the drug has been found.
Catalog record
| CREATOR | C. Inagaki, E. Oki, K. Ando, H. Hirano, M. Furuta, Y. Narita, T. Esaki, K. Murotani, H. Kawakami, K. Muro |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |